Pacer Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Pacer Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,073	Closed	-$118K	–	1169
2018 Q3	$118K	Buy	+7,073	New	+$128K	﹤0.01%	1072
2018 Q1	–	Sell	-3,850	Closed	-$44K	–	1180
2017 Q4	$44K	Buy	+3,850	New	+$43K	﹤0.01%	1030

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pacer Advisors's ALDR Position: Q4 2018 in Review

Pacer Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 7,073 shares — an estimated $118K sold.

Pacer Advisors first reported a position in ALDR in Q4 2017 and held it in 2 quarters. The position peaked at $118K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Pacer Advisors reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Pacer Advisors sold 7,073 Alder Biopharmaceuticals shares in Q4 2018, an estimated $118K.
Pacer Advisors first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 2 quarters.
Pacer Advisors's Alder Biopharmaceuticals position peaked at $118K in Q3 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.